Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Cancer Res. 2009 Oct 20;69(21):8302–8309. doi: 10.1158/0008-5472.CAN-09-0798

Figure 3. Comparison of predictive performance of COXEN-based GEMs to conventional patient data-derived GEMs.

Figure 3

Patient disease-free (DFS) or overall (OS) survival prediction was performed either by the COXEN-derived GEM stratification of MVAC (COXEN-GEM) used in Figure 2A or that using conventional human patient-based approach (Takata-GEM).(4) Kaplan-Meier survival analysis by (A) COXEN-GEM on the whole BL-Jap set (N=45), (B) COXEN-GEM on the test subset of BL-Jap (N=27), (C) Takata-GEM on the whole BL-Jap set (N=45), (D) Takata-GEM on the test subset of BL-Jap (N=27), (E) COXEN-GEM on the BL-Den set (N=14), and (F) Takata-GEM on the BL-Den set (N=14). P-values by log-rank test.